Experimental Investigation of Ingavirin® Antiviral Activity Against Human Parainfluenza Virus
Abstract
The Ingavirin® antiviral properties with respect to the parainfluenza virus, as an actual human respiratory tract pathogen, were investigated by two methods, i.e. immunoenzymatic analysis and microtetrazolium test. The results showed that along with the immediate antiviral activity Ingavirin® had nonspecific cytoprotective properties. While affecting the virus proteins synthesis, Ingavirin® lowered the virus cytopathogenic action. The drug significantly decreased the portion of the bronchial epithelium cells killed at the stage of acute infection.
About the Authors
V. V. Zarubaev
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
V. Z. Krivitskaya
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
V. E. Nebolsin
Valenta Farm Co.
Russian Federation
Russian Federation
O. I. Kiselev
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Henrickson K. J. Parainfluenza viruses. Clin Microbiol Rev. 2003; 16: 242-264.
2. Abed Y., Boivin G. Treatment of respiratory virus infections. Antiviral Res. 2006; 70: 2: 1-16.
3. Alymova I. V., Taylor G., Takimoto T. et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother 2004; 48: 5: 1495-502.
4. Saladino R., Ciambecchini U., Nencioni L., Palamara A. T. Recent advances in the chemistry of parainfluenza-1 (Sendai) virus inhibitors. Med Res Rev 2003; 23: 4: 427-455.
5. De Franceschi L., Fattovich G., Turrini F. et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 4: 997-1004.
6. Prince G. A., Porter D. D. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J Infect Dis 1996; 173: 3: 598-608.
7. Логинова С. Я., Борисевич С. В., Лыков М. В. и др. Изучение эффективности Ингавирина® in vitro в отношении «мексиканского» пандемического подтипа H1N1 вируса гриппа А, штаммы A/California/04/2009 и A/California/07/2009. Антибиотики и химиотер 2009; 3-4: 15-17.
8. Логинова С. Я., Борисевич С. В., Максимов В. А. и др. Изучение терапевтической эффективности нового отечественного препарата Ингавирин® в отношении возбудителя гриппа А (H3N2). Антибиотики и химиотер 2008; 53: 11/12: 27-30.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
10. Зарубаев В. В., Гаршинина А. В., Калинина Н. А. и др. Протективная активность препарата Ингавирин® при экспериментальной летальной гриппозной инфекции белых мышей, вызванной пандемическим вирусом гриппа A(H1N1)v. Антибиотики и химиотерапия 2010; 5-6:
Review
For citations:
Zarubaev V.V., Krivitskaya V.Z., Nebolsin V.E., Kiselev O.I. Experimental Investigation of Ingavirin® Antiviral Activity Against Human Parainfluenza Virus. Antibiot Khimioter = Antibiotics and Chemotherapy. 2010;55(7-8):13. (In Russ.)
Views:
313
Email this article 